Fig. 2: Retroviral and lentiviral-transduced cell engraftment kinetics in patient NYSCT-01. | Nature Communications

Fig. 2: Retroviral and lentiviral-transduced cell engraftment kinetics in patient NYSCT-01.

From: Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

Fig. 2

A Peripheral NY-ESO-1 TCR+ expansion and contraction over time in vivo. B Vector copy number (VCN) kinetics in peripheral circulation. While there was a predominance of retrovirus (RV)-derived product early, there was predominantly lentiviral (LV)-derived product coinciding with the day +29 [18 F]-FHBG PET (C), followed by a loss of LV-derived product coinciding with the day +120 PET scan (D). Data in 2B represent two experimental replicates, ± SD.

Back to article page